Depatuxizumab mafodotin - AbbVie
Alternative Names: ABT-414; ABT-414/806; Depatux-MLatest Information Update: 15 Dec 2023
At a glance
- Originator Abbott Laboratories
- Developer AbbVie
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Glioblastoma; Gliosarcoma; Non-small cell lung cancer; Solid tumours